Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

Same day tools, including Xpert Ultra and unstimulated IFN-γ, for the rapid diagnosis of pleural tuberculosis - a prospective observational study.

Meldau R, Randall P, Pooran A, Limberis J, Makambwa E, Dhansay M, Esmail A, Dheda K.

J Clin Microbiol. 2019 Jul 3. pii: JCM.00614-19. doi: 10.1128/JCM.00614-19. [Epub ahead of print]

2.

Linezolid interruption in patients with fluoroquinolone-resistant tuberculosis receiving a bedaquiline-based treatment regimen.

Olayanju O, Esmail A, Limberis J, Gina P, Dheda K.

Int J Infect Dis. 2019 May 14;85:74-79. doi: 10.1016/j.ijid.2019.04.028. [Epub ahead of print]

3.

Design and Synthesis of Novel and Selective Glycine Transporter-1 (GlyT1) Inhibitors with Memory Enhancing Properties.

Santora VJ, Almos TA, Barido R, Basinger J, Bellows CL, Bookser BC, Breitenbucher JG, Broadbent NJ, Cabebe C, Chai CK, Chen M, Chow S, Chung M, Crickard L, Danks AM, Freestone GC, Gitnick D, Gupta V, Hoffmaster C, Hudson AR, Kaplan AP, Kennedy MR, Lee D, Limberis J, Ly K, Mak CC, Masatsugu B, Morse AC, Na J, Neul D, Nikpur J, Peters M, Petroski RE, Renick J, Sebring K, Sevidal S, Tabatabaei A, Wen J, Yan Y, Yoder ZW, Zook D.

J Med Chem. 2018 Jul 26;61(14):6018-6033. doi: 10.1021/acs.jmedchem.8b00372. Epub 2018 Jul 11.

PMID:
29886732
4.

Long-term bedaquiline-related treatment outcomes in patients with extensively drug-resistant tuberculosis from South Africa.

Olayanju O, Limberis J, Esmail A, Oelofse S, Gina P, Pietersen E, Fadul M, Warren R, Dheda K.

Eur Respir J. 2018 May 30;51(5). pii: 1800544. doi: 10.1183/13993003.00544-2018. Print 2018 May.

PMID:
29700106
5.

Eleclazine exhibits enhanced selectivity for long QT syndrome type 3-associated late Na+ current.

El-Bizri N, Xie C, Liu L, Limberis J, Krause M, Hirakawa R, Nguyen S, Tabuena DR, Belardinelli L, Kahlig KM.

Heart Rhythm. 2018 Feb;15(2):277-286. doi: 10.1016/j.hrthm.2017.09.028. Epub 2017 Oct 7.

PMID:
29017927
6.

Discovery of Selective Phosphodiesterase 1 Inhibitors with Memory Enhancing Properties.

Dyck B, Branstetter B, Gharbaoui T, Hudson AR, Breitenbucher JG, Gomez L, Botrous I, Marrone T, Barido R, Allerston CK, Cedervall EP, Xu R, Sridhar V, Barker R, Aertgeerts K, Schmelzer K, Neul D, Lee D, Massari ME, Andersen CB, Sebring K, Zhou X, Petroski R, Limberis J, Augustin M, Chun LE, Edwards TE, Peters M, Tabatabaei A.

J Med Chem. 2017 Apr 27;60(8):3472-3483. doi: 10.1021/acs.jmedchem.7b00302. Epub 2017 Apr 13.

PMID:
28406621
7.

Selected questions and controversies about bedaquiline: a view from the field.

Dheda K, Esmail A, Limberis J, Maartens G.

Int J Tuberc Lung Dis. 2016 Dec 1;20(12):24-32. doi: 10.5588/ijtld.16.0065. Review.

PMID:
28240569
8.

Outcomes, infectiousness, and transmission dynamics of patients with extensively drug-resistant tuberculosis and home-discharged patients with programmatically incurable tuberculosis: a prospective cohort study.

Dheda K, Limberis JD, Pietersen E, Phelan J, Esmail A, Lesosky M, Fennelly KP, Te Riele J, Mastrapa B, Streicher EM, Dolby T, Abdallah AM, Ben-Rached F, Simpson J, Smith L, Gumbo T, van Helden P, Sirgel FA, McNerney R, Theron G, Pain A, Clark TG, Warren RM.

Lancet Respir Med. 2017 Apr;5(4):269-281. doi: 10.1016/S2213-2600(16)30433-7. Epub 2017 Jan 19.

PMID:
28109869
9.

Xpert MTB/RIF Results in Patients With Previous Tuberculosis: Can We Distinguish True From False Positive Results?

Theron G, Venter R, Calligaro G, Smith L, Limberis J, Meldau R, Chanda D, Esmail A, Peter J, Dheda K.

Clin Infect Dis. 2016 Apr 15;62(8):995-1001. doi: 10.1093/cid/civ1223. Epub 2016 Feb 16.

10.

Negative inotropic effect of a CB2 agonist A-955840 in isolated rabbit ventricular myocytes is independent of CB1 and CB2 receptors.

Su Z, Preusser L, Diaz G, Green J, Liu X, Polakowski J, Dart M, Yao B, Meyer M, Limberis JT, Martin RL, Cox BF, Gintant GA.

Curr Drug Saf. 2011 Nov 1;6(5):277-84.

PMID:
22424534
11.

Characterization of A-935142, a hERG enhancer, in the presence and absence of standard hERG blockers.

Liu X, Limberis JT, Su Z, Houseman K, Diaz GJ, Gintant GA, Cox BF, Martin RL.

Life Sci. 2012 Apr 20;90(15-16):607-11. doi: 10.1016/j.lfs.2012.02.017. Epub 2012 Mar 3.

PMID:
22406079
12.

Ventricular rate adaptation: a novel, rapid, cellular-based in-vitro assay to identify proarrhythmic and torsadogenic compounds.

Green JR, Diaz GJ, Limberis JT, Houseman KA, Su Z, Martin RL, Cox BF, Kantor S, Gintant GA.

J Pharmacol Toxicol Methods. 2011 Jul-Aug;64(1):68-73. doi: 10.1016/j.vascn.2011.03.005. Epub 2011 Apr 2.

PMID:
21440075
13.

Comparative analysis of inactivated-state block of N-type (Ca(v)2.2) calcium channels.

Vortherms TA, Swensen AM, Niforatos W, Limberis JT, Neelands TR, Janis RS, Thimmapaya R, Donnelly-Roberts DL, Namovic MT, Zhang D, Brent Putman C, Martin RL, Surowy CS, Jarvis MF, Scott VE.

Inflamm Res. 2011 Jul;60(7):683-93. doi: 10.1007/s00011-011-0322-9. Epub 2011 Mar 11.

PMID:
21394563
14.

A novel secretagogue increases cardiac contractility by enhancement of L-type Ca2+ current.

Su Z, Widomski DL, Liu X, Limberis JT, Green J, Diaz G, Martin RL, Cox BF, Gintant GA.

Biochem Pharmacol. 2010 Oct 1;80(7):1000-6. doi: 10.1016/j.bcp.2010.06.006. Epub 2010 Jun 22.

PMID:
20599796
15.

Electrophysiologic characterization of a novel hERG channel activator.

Su Z, Limberis J, Souers A, Kym P, Mikhail A, Houseman K, Diaz G, Liu X, Martin RL, Cox BF, Gintant GA.

Biochem Pharmacol. 2009 Apr 15;77(8):1383-90. doi: 10.1016/j.bcp.2009.01.015. Epub 2009 Feb 3.

PMID:
19426677
16.

Functional consequences of methionine oxidation of hERG potassium channels.

Su Z, Limberis J, Martin RL, Xu R, Kolbe K, Heinemann SH, Hoshi T, Cox BF, Gintant GA.

Biochem Pharmacol. 2007 Sep 1;74(5):702-11. Epub 2007 Jun 7.

17.

Hydroxypropyl beta-cyclodextrins: a misleading vehicle for the in vitro hERG current assay.

Mikhail A, Fischer C, Patel A, Long MA, Limberis JT, Martin RL, Cox BF, Gintant GA, Su Z.

J Cardiovasc Pharmacol. 2007 May;49(5):269-74.

PMID:
17513944
18.

The effects of plasma proteins on delayed repolarization in vitro with cisapride, risperidone, and D, L-sotalol.

Limberis JT, McDermott JS, Salmen HJ, Su Z, Mikhail A, Green JR, Cox BF, Gintant GA, Martin RL.

J Pharmacol Toxicol Methods. 2007 Jul-Aug;56(1):11-7. Epub 2007 Feb 12.

PMID:
17350293
19.

Identification of diamino chromone-2-carboxamides as MCHr1 antagonists with minimal hERG channel activity.

Judd AS, Souers AJ, Wodka D, Zhao G, Mulhern MM, Iyengar RR, Gao J, Lynch JK, Freeman JC, Falls HD, Brodjian S, Dayton BD, Reilly RM, Gintant G, Limberis JT, Mikhail A, Leitza ST, Houseman KA, Diaz G, Bush EN, Shapiro R, Knourek-Segel V, Hernandez LE, Marsh KC, Sham HL, Collins CA, Kym PR.

Bioorg Med Chem Lett. 2007 Apr 15;17(8):2365-71. Epub 2006 Dec 1.

PMID:
17350253
20.

In vitro preclinical cardiac assessment of tolterodine and terodiline: multiple factors predict the clinical experience.

Martin RL, Su Z, Limberis JT, Palmatier JD, Cowart MD, Cox BF, Gintant GA.

J Cardiovasc Pharmacol. 2006 Nov;48(5):199-206.

PMID:
17110801
21.

Optimization of chromone-2-carboxamide melanin concentrating hormone receptor 1 antagonists: assessment of potency, efficacy, and cardiovascular safety.

Lynch JK, Freeman JC, Judd AS, Iyengar R, Mulhern M, Zhao G, Napier JJ, Wodka D, Brodjian S, Dayton BD, Falls D, Ogiela C, Reilly RM, Campbell TJ, Polakowski JS, Hernandez L, Marsh KC, Shapiro R, Knourek-Segel V, Droz B, Bush E, Brune M, Preusser LC, Fryer RM, Reinhart GA, Houseman K, Diaz G, Mikhail A, Limberis JT, Sham HL, Collins CA, Kym PR.

J Med Chem. 2006 Nov 2;49(22):6569-84.

PMID:
17064075
22.

Altering extracellular potassium concentration does not modulate drug block of human ether-a-go-go-related gene (hERG) channels.

Limberis JT, Su Z, Cox BF, Gintant GA, Martin RL.

Clin Exp Pharmacol Physiol. 2006 Nov;33(11):1059-65.

PMID:
17042915
23.

Parallel synthesis of a biased library of thiazolidinones as novel sodium channel antagonists.

Sun Q, Tafesse L, Limberis JT, Islam K, Kyle DJ.

Comb Chem High Throughput Screen. 2003 Aug;6(5):481-8. Review.

PMID:
12871054
24.

N-(4-tertiarybutylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine -1(2H)-carbox-amide (BCTC), a novel, orally effective vanilloid receptor 1 antagonist with analgesic properties: I. in vitro characterization and pharmacokinetic properties.

Valenzano KJ, Grant ER, Wu G, Hachicha M, Schmid L, Tafesse L, Sun Q, Rotshteyn Y, Francis J, Limberis J, Malik S, Whittemore ER, Hodges D.

J Pharmacol Exp Ther. 2003 Jul;306(1):377-86. Epub 2003 Apr 29.

PMID:
12721338
25.

The canine Purkinje fiber: an in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis.

Gintant GA, Limberis JT, McDermott JS, Wegner CD, Cox BF.

J Cardiovasc Pharmacol. 2001 May;37(5):607-18.

PMID:
11336111
26.
27.

Transitional changes in membrane potential and intracellular [Ca2+] in rat basophilic leukemia cells.

Mason MJ, Limberis J, Schofield GG.

J Membr Biol. 1999 Jul 1;170(1):79-87.

PMID:
10398762
28.

Coexpression of beta 1 with cardiac sodium channel alpha subunits in oocytes decreases lidocaine block.

Makielski JC, Limberis JT, Chang SY, Fan Z, Kyle JW.

Mol Pharmacol. 1996 Jan;49(1):30-9.

PMID:
8569709
29.

The saxitoxin/tetrodotoxin binding site on cloned rat brain IIa Na channels is in the transmembrane electric field.

Satin J, Limberis JT, Kyle JW, Rogart RB, Fozzard HA.

Biophys J. 1994 Sep;67(3):1007-14.

Supplemental Content

Loading ...
Support Center